Key facts
- Sensorium Therapeutics’s last known valuation is $47.0M (Sep 2022).
- It has raised $69.7M across 3 recorded rounds; the latest was Early Stage VC ($26.8M) in Jan 2025.
- Notable investors include Service Provider Capital, Dolby Family Ventures, Hatteras Venture Partners, Mission BioCapital, Ocama Partners — 16 tracked in total.
- Sensorium Therapeutics has filed 5 Form Ds with the SEC since 2021, most recently Jul 2025 ($26.8M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Sensorium Therapeutics
Funding rounds
3 roundsAbout Sensorium Therapeutics
Developer of a therapeutic discovery platform designed to identify compounds for treating brain and mental health conditions. The company's platform utilizes a computational approach that integrates artificial intelligence, chemistry, and neuroscience to accelerate the identification of new drug candidates, enabling researchers and clinicians to develop novel treatments and provide patients with access to effective therapeutic options that address significant unmet medical needs.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 26
- Website
- sensorium.bio/
- Ownership
- Privately Held (backing)
Sensorium Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sensorium Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sensorium Therapeutics in its N-PORT filings yet. We sweep new filings monthly.